Integra LifeSciences (NASDAQ:IART) Sets New 1-Year Low - Time to Sell?

Integra LifeSciences Holdings Co. (NASDAQ:IART - Get Free Report) shares reached a new 52-week low on Monday . The stock traded as low as $14.45 and last traded at $14.67, with a volume of 194595 shares. The stock had previously closed at $15.83.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. Truist Financial reduced their target price on Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating on the stock in a report on Friday, April 11th. Argus upgraded Integra LifeSciences from a "hold" rating to a "buy" rating in a research note on Monday, March 31st. Three research analysts have rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Hold" and an average target price of $22.71.

Integra LifeSciences Price Performance

The company has a market cap of $1.27 billion, a price-to-earnings ratio of -183.31, a P/E/G ratio of 0.73 and a beta of 1.24. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79. The business has a 50-day moving average price of $20.64 and a 200 day moving average price of $22.19.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last announced its earnings results on Tuesday, February 25th. The life sciences company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.85 by $0.12. The business had revenue of $442.65 million during the quarter, compared to the consensus estimate of $445.15 million. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. Integra LifeSciences's revenue was up 11.5% compared to the same quarter last year. During the same period in the prior year, the business posted $0.89 earnings per share. As a group, research analysts expect that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in IART. Principal Financial Group Inc. grew its stake in shares of Integra LifeSciences by 18.7% in the 3rd quarter. Principal Financial Group Inc. now owns 401,432 shares of the life sciences company's stock valued at $7,294,000 after buying an additional 63,266 shares in the last quarter. Norges Bank bought a new stake in Integra LifeSciences in the fourth quarter worth approximately $8,967,000. Arrowstreet Capital Limited Partnership increased its stake in shares of Integra LifeSciences by 7.1% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 13,756 shares of the life sciences company's stock worth $312,000 after purchasing an additional 913 shares during the last quarter. Nisa Investment Advisors LLC raised its holdings in shares of Integra LifeSciences by 599.6% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company's stock valued at $74,000 after purchasing an additional 2,800 shares in the last quarter. Finally, PNC Financial Services Group Inc. lifted its stake in shares of Integra LifeSciences by 33.6% in the 4th quarter. PNC Financial Services Group Inc. now owns 19,755 shares of the life sciences company's stock valued at $448,000 after purchasing an additional 4,967 shares during the last quarter. Institutional investors and hedge funds own 84.78% of the company's stock.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.